Suppr超能文献

脑转移瘤切除腔的立体定向放射外科治疗:预后因素与结果

Stereotactic radiosurgery to the resection cavity for brain metastases: prognostic factors and outcomes.

作者信息

Abel Ryan J, Ji Lingyun, Yu Cheng, Lederman Ariel, Chen Thomas, Liu Charles, Zada Gabriel, Kim Paul E, Apuzzo Michael, Chang Eric L

机构信息

Keck USC School of Medicine Department of Radiation Oncology,1441 Eastlake Avenue, Los Angeles, CA 90033, USA.

USC Department of Preventive Medicine, 1501 San Pablo Street, ZNI 101, Los Angeles CA 90033, USA.

出版信息

J Radiosurg SBRT. 2015;3(3):179-186.

Abstract

BACKGROUND

Adjuvant stereotactic radiosurgery (SRS) alone after surgical resection is increasingly being used to provide excellent local control while avoiding the side effects of whole brain radiation therapy (WBRT). We report our ten year experience using this treatment scheme.

PURPOSE/OBJECTIVES: To determine the rates and any correlates of local control, distant brain failure, and overall survival using SRS alone to the resection cavity.

MATERIALS/METHODS: We performed a retrospective analysis of 509 patients with brain metastasis who underwent Gamma Knife SRS at our institution between 2003 and 2013. Of this group 85 patients were identified that had resection of the metastasis and subsequent SRS to the cavity. Mean dose to the resection cavity was 17.3 Gy (range 14-20) to an average volume of 12cc (range 0.3-83cc). Multiple patient, tumor, and treatment specific factors were collected for analysis (see Table 1). Vital statistics were provided by our institution's tumor registry. The primary endpoint of our analyses was recurrence free survival (RFS); defined as the duration in time between the date of SRS and any local or distant brain tumor recurrence.

RESULTS

With a median follow up of 16.4 months, the overall local and distant brain failure at 12 months was 13% (95%CI 5%-21%) and 51% (95%CI 37%-64%) respectively. RPA was class 1 (5%), 2 (75%), and 3 (20%). The median overall survival (OS) was 20 months. The median RFS was 24 months with radiosensitive tumors: non small cell lung cancer (n=12), breast (n=16), gastrointestinal (n=7), small cell lung cancer (n=1), and other (n=9) compared to 5.6 months (p=0.006) in radioresistant tumors: melanoma (n=33), sarcoma (n=1), and renal cell carcinoma (n=6). Median OS for radioresistant and radiosensitive patients was 12 vs 25 months respectively (p=0.11). Additionally, there was a significant improved survival difference seen amongst those who had a gross total resection (GTR, n=46) compared to a sub total resection (n=39) with median OS of 27 vs 16 months (p=0.020) respectively. Radiographic changes suggestive of radiation necrosis were present in 6 patients, 2 of which were determined histiopathologicaly after surgical intervention. Due to the limited number of local recurrence events (n=10), there was insufficient power to analyze prognostic factors for local recurrence.

CONCLUSIONS

Our results compare favorably with multiple other institution experiences showing excellent local control with SRS to the resection cavity following resection. Radioresistant histologies were associated with a worse RFS. Patients undergoing GTR had a significantly longer OS than those with STR. At our institution we continue to offer patients SRS to the resection cavity for those with good performance status and limited brain metastases.

摘要

背景

手术切除后单独使用辅助立体定向放射外科(SRS)越来越多地用于实现良好的局部控制,同时避免全脑放射治疗(WBRT)的副作用。我们报告了我们使用这种治疗方案的十年经验。

目的

确定单独使用SRS治疗切除腔的局部控制率、远处脑转移失败率及总生存率,并分析相关因素。

材料与方法

我们对2003年至2013年间在我院接受伽玛刀SRS治疗的509例脑转移患者进行了回顾性分析。其中85例患者进行了转移灶切除并随后对切除腔进行了SRS治疗。切除腔的平均剂量为17.3 Gy(范围14 - 20),平均体积为12cc(范围0.3 - 83cc)。收集了多个患者、肿瘤及治疗相关因素进行分析(见表1)。生存统计数据由我院肿瘤登记处提供。我们分析的主要终点是无复发生存期(RFS),定义为SRS治疗日期至任何局部或远处脑肿瘤复发的时间间隔。

结果

中位随访时间为16.4个月,12个月时的总体局部和远处脑转移失败率分别为13%(95%CI 5% - 21%)和51%(95%CI 37% - 64%)。递归分区分析(RPA)分级为1级(5%)、2级(75%)和3级(20%)。中位总生存期(OS)为20个月。放射敏感肿瘤(非小细胞肺癌,n = 12;乳腺癌,n = 16;胃肠道肿瘤,n = 7;小细胞肺癌,n = 1;其他,n = 9)的中位RFS为24个月,而放射抗拒肿瘤(黑色素瘤,n = 33;肉瘤,n = 1;肾细胞癌,n = 6)的中位RFS为5.6个月(p =  0.006)。放射抗拒和放射敏感患者的中位OS分别为12个月和25个月(p = 0.11)。此外,与次全切除(n = 39)的患者相比,接受全切除(GTR,n = 46)的患者生存差异有显著改善,中位OS分别为27个月和16个月(p = 0.020)。6例患者出现提示放射性坏死的影像学改变,其中2例在手术干预后经组织病理学确诊。由于局部复发事件数量有限(n = 10),分析局部复发的预后因素的效能不足。

结论

我们的结果与其他多个机构的经验相比具有优势,显示出切除后对切除腔进行SRS可实现良好的局部控制。放射抗拒组织学类型与较差的RFS相关。接受GTR的患者OS明显长于接受次全切除的患者。在我院,对于身体状况良好且脑转移局限的患者,我们继续为其提供对切除腔进行SRS治疗。

相似文献

引用本文的文献

9
Current approaches to the management of brain metastases.脑转移瘤的治疗方法。
Nat Rev Clin Oncol. 2020 May;17(5):279-299. doi: 10.1038/s41571-019-0320-3. Epub 2020 Feb 20.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验